Benefits opioid painkiller opana er no longer outweigh its risks FDA panel says

The FDA has accepted for review a new drug application for CL-108 (Charleston Laboratories/Daiichi Sankyo) for the relief of moderate-to-severe pain while preventing or reducing the associated opioid-induced nausea and vomiting. CL-108 is a fixed-dose, immediate-release, bilayered tablet with a rapid-release layer containing 12.5 mg of promethazine and a second layer containing 7.5 mg of hydrocodone and 325 mg of acetaminophen.

The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 31, 2017.

The new drug application for CL-108 was supported by two pivotal randomized, double-blind, placebo- and active-controlled phase 3 clinical studies, one after oral surgery (molar removal) and the other after bunionectomy surgery, as well as by an additional phase 3 open-label, actual-use safety study in patients with moderate-to-severe acute pain or “flares” associated with osteoarthritis of the knee or hip. More than 1,000 patients have been enrolled in the CL-108 phase 3 clinical trial program. A human abuse-liability study has also been conducted.

Source: Charleston Laboratories; June 14, 2016.

More Headlines

National professional organization is updating, revamping, and expanding programs
N-acetylcysteine shows benefit in a preliminary clinical trial
German Scientists Discover Molecular Mechanism of Thalidomide
Disruption of protein complex causes both birth defects and anticancer activity
Study Finds Statin Drugs Reduce Infection Risk in Stroke Patients
Timing of administration is crucial
Potential Drug Target Identified for Zika and Similar Flaviviruses
Shutting down a single gene may disrupt the viruses from spreading in the body
New Genetic Research Can Significantly Improve Drug Development
Biobank studies can improve pipeline and reduce costs
Positive Top-Line Results Reported for Orphan Drug CCX168 in Treatment of ANCA-Associated Vasculitis
Drug aims to reduce or eliminate use of chronic high-dose steroids in treating the disease
Positive Phase 3 Results Reported for Keytruda in Patients With Advanced NSCLC
Merck’s immunotherapy demonstrated superior progression-free and overall survival
Tenofovir lowers transmission rate by 13 percentage points

Our most popular topics on Managedcaremag.com